Preclinical Assessment of Candidate Analgesic Drugs: Recent Advances and Future Challenges
- 2 June 2006
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 319 (2), 507-514
- https://doi.org/10.1124/jpet.106.106377
Abstract
In analgesic drug development, preclinical procedures are widely used to assess drug effects on pain-related behaviors. These procedures share two principal components: 1) a manipulation intended to produce a pain-like state in the experimental subject and 2) measurement of behaviors presumably indicative of that pain state. Drugs can then be evaluated for their ability to attenuate pain-related behaviors. In the simplest procedures, the pain state is produced by delivery of an acute noxious stimulus (e.g., a warm thermal stimulus), and the primary dependent measures focus on withdrawal responses or other nocifensive behaviors that increase in rate, frequency, or intensity in response to the noxious stimulus. This approach has been refined in two ways. First, new methods have been developed to induce more clinically relevant pain states. In particular, pain requiring clinical intervention is often associated with inflammation or neuropathy, and novel procedures have emerged to model these conditions and their ability to produce hypersensitive pain states, such as allodynia and hyperalgesia. Second, studies are incorporating a broader array of pain-related behaviors as dependent measures. For example, pain not only stimulates nocifensive behaviors but also suppresses many adaptive behaviors, such as feeding or locomotion. Measures of pain-suppressed behaviors can provide new insights into the behavioral consequences of pain and the effects of candidate analgesics. In addition, functional magnetic resonance imaging has emerged as a noninvasive tool for investigating changes in neural activity associated with pain and analgesia. Integration of these complementary approaches may improve the predictive validity of analgesic drug development.This publication has 43 references indexed in Scilit:
- Clinically important outcomes in low back painBest Practice & Research Clinical Rheumatology, 2005
- The Role of Central and Peripheral μ Opioid Receptors in Inflammatory Pain and Edema: A Study Using Morphine and DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic Acid)The Journal of pharmacology and experimental therapeutics, 2005
- Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki RatsLife Sciences, 2005
- What should we be measuring in behavioral studies of chronic pain in animals?Pain, 2004
- Pain related behaviour in two models of osteoarthritis in the rat kneePain, 2004
- Evaluation of analgesic and anti-inflammatory activities of Nectandra megapotamica (Lauraceae) in mice and ratsJournal of Pharmacy and Pharmacology, 2004
- Effects of Laparotomy on Spontaneous Exploratory Activity and Conditioned Operant Responding in the RatAnesthesiology, 2004
- Pharmacological fMRI: A New Tool for Drug Development in HumansJournal of Pharmacy Practice, 2001
- Animal Models of PainPublished by Taylor & Francis Ltd ,2001
- Assessing Nociception in Murine SubjectsPublished by Taylor & Francis Ltd ,2001